POZ changes the treatment paradigm for PARKINSONS DISEASE.
Parkinson’s treatment has not really changed in 50 years. As many as ten million people worldwide may be affected by the disease. Patients with advancing disease frequently develop “OFF” time – their existing medications simply do not allow them to perform even routine activities. They are invariably treated with L-DOPA to control their symptoms and over time invariably develop dyskinesia (involuntary motor fluctuation) due to the phasic peak/trough nature of short acting dopamine drugs.
There is a significant unmet need for continuous dopaminergic stimulation.
Apomorphine (a dopamine agonist) is the “holy grail” of dopamine therapy in advanced disease – capable of reversing “OFF” periods within minutes. But the current formulations are confounded by severe skin reactions, and it must be delivered via a continuous subcutaneous electronic infusion device each day. This often requires a health care provider to set it up daily.
SER-252 POZ-apomorphine is a potential breakthrough therapy for advanced disease, delivered as a single injection once a week.
Reducing “OFF” time, with no adverse skin reactions and no need for a doctor or nurse to administer it. SER-252 is a preventive therapy (not a rescue therapy) with the potential to increase “ON” time, prevent dyskinesia, and may allow some patients to titrate off all L-DOPA.